Trinity Delta - Avacta: Encouraging first data from AVA6103 Phase Ia study
Research on Avacta Group PLC (AVCT:LON) from Trinity Delta
Avacta is a differentiated clinical-stage oncology specialist, increasingly defined by continuing progress with its second-generation pre|CISION tumour-activated Peptide Drug Conjugate (PDC) platform. The lead Gen Two programme, AVA6103 (FAP-EXd, a FAP-activated, controlled-release exatecan), has delivered initial Phase Ia safety and pharmacokinetic data from the FOCUS-01 trial. These data provide early human validation that the platform successfully replicates the targeted tissue localisation seen in preclinical models. They show a three-fold reduction in systemic payload exposure compared to market-leading antibody-drug conjugate (ADC) benchmarks and avoid the severe myelosuppression typically associated with free topoisomerase I inhibitors. Further clinical news flow over the next 12 months should establish the utility, positioning, and value of the pre|CISION platform. Our rNPV-based valuation is £525m/$671m, equivalent to 111p/share.
View Full ResearchDisclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
